NCT00003615 2023-06-15
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
9 trialsNCT00117845 2019-11-19
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01106950 2017-12-28
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00082940 2017-01-19
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT00026429 2013-12-18
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00138164 2013-05-30
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00224354 2012-05-21
CLONTAK
Baylor College of Medicine
Phase 1 Withdrawn
NCT00493129 2012-02-08
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00055146 2009-04-17
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
Eisai Inc.
Phase 2 Completed